The Terrible, Horrible, No Good, Very Bad Pharma Day* A challenge You are passionate about providing an intervention (drug or device) to a group… September 29, 2015 Uncategorized
None Better than One? (A Brief Note on VC in Smaller Hubs) Biotech venture funding metrics continue at historic highs, highlighting that the robust financing environment… May 20, 2015 Uncategorized
Blood: Underappreciated Resource in the Health/Disease? Alternative title: Pitching a VC on Disruption of Blood Testing You may have seen… May 5, 2015 Uncategorized
Case Study: When does “technology” turn into medical device This semester I've embarked on an adventure to co-teach a class in the University… February 8, 2015 Uncategorized
What is the optimal biotech burn rate? Ethan Perlstein, founder of Perlstein Lab, asked a question on Twitter and got some great… February 2, 2015 Uncategorized
Innovation: Via a 5th Generation WI Life Science Company I want to share three themes that struck me from the Dohmen Life Science Services… October 25, 2014 Uncategorized
Could Pharma/Biotech Build an Amazon? Pharma/Biotech Business Model Innovation When I hear/read about business model innovation in pharma/biotech, the themes… August 26, 2014 Uncategorized
Biotech: Outside Looking In In a post in March, I suggested that I would represent the "less glamorous… July 2, 2014 Uncategorized
(Re)Reading This Weekend (6/14/14) There were a few long reads that I'll be re-reading over the weekend, including: New… June 14, 2014 Uncategorized
Risk Distribution & Opportunity Costs in Entrepreneurship Risk Distribution In WIRED, "One Startup’s Struggle to Survive the Silicon Valley Gold Rush"… May 23, 2014 Uncategorized